SE7409366L - - Google Patents

Info

Publication number
SE7409366L
SE7409366L SE7409366A SE7409366A SE7409366L SE 7409366 L SE7409366 L SE 7409366L SE 7409366 A SE7409366 A SE 7409366A SE 7409366 A SE7409366 A SE 7409366A SE 7409366 L SE7409366 L SE 7409366L
Authority
SE
Sweden
Prior art keywords
biocatalyst
polyalkyl
polyalkoxy
polyalkoxy polymer
unsubstituted
Prior art date
Application number
SE7409366A
Other versions
SE441753B (en
Inventor
F F Davis
Es T Van
N C Palczuk
Original Assignee
Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp filed Critical Research Corp
Publication of SE7409366L publication Critical patent/SE7409366L/xx
Publication of SE441753B publication Critical patent/SE441753B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method for suppressing the immunogenic action of a biocatalyst which has a large number of peptide linkages, with at least partial retention of its physiological activity, entails attaching polymers to the biocatalyst; the biocatalyst is attached to a virtually linear polyalkyl or polyalkoxy polymer via at least one terminal carbon atom thereof; the polyalkyl or polyalkoxy polymer is unsubstituted or substituted by an alkoxy or alkyl group containing fewer than 5 C atoms.
SE7409366A 1973-07-20 1974-07-18 SET TO MAKE A PROTECTED POLYPEPTIME WITH Diminished Prone to Immunization and Behavioral Physiological Activity SE441753B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38119173A 1973-07-20 1973-07-20

Publications (2)

Publication Number Publication Date
SE7409366L true SE7409366L (en) 1975-01-21
SE441753B SE441753B (en) 1985-11-04

Family

ID=23504063

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7409366A SE441753B (en) 1973-07-20 1974-07-18 SET TO MAKE A PROTECTED POLYPEPTIME WITH Diminished Prone to Immunization and Behavioral Physiological Activity

Country Status (9)

Country Link
JP (1) JPS5623587B2 (en)
CA (1) CA1033673A (en)
CH (1) CH616942A5 (en)
DE (1) DE2433883C2 (en)
FR (1) FR2313939A1 (en)
GB (1) GB1469472A (en)
IL (1) IL45291A0 (en)
NL (1) NL7409770A (en)
SE (1) SE441753B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2930542A1 (en) * 1979-07-27 1981-02-12 Hoechst Ag NEW INSULINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
JPS59204130A (en) * 1983-04-30 1984-11-19 Nippon Chemiphar Co Ltd Oral administration drug containing novel plasminogen activator derivative
DE3334407A1 (en) * 1983-09-23 1985-04-04 Hoechst Ag, 6230 Frankfurt INSULINE DERIVATIVES MODIFIED IN POSITION B 30, METHOD FOR THE PRODUCTION AND USE THEREOF AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF THE DIABETES MELLITUS
JPS61163687U (en) * 1985-03-28 1986-10-09
JPS62207485A (en) * 1986-03-07 1987-09-11 大平技研工業株式会社 Television game machine
US5037969A (en) * 1986-07-03 1991-08-06 Takeda Chemical Industries, Ltd. Glycosyl derivatives and use thereof
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5578496A (en) * 1991-12-19 1996-11-26 Board Of Regents, Baylor College Of Medicine Detection of autoantibodies associated with the disease myasthenia gravis
AU3423293A (en) * 1991-12-19 1993-07-19 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
JP5020451B2 (en) * 1999-09-10 2012-09-05 ザ プロクター アンド ギャンブル カンパニー Enzyme inhibitor
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
EP2305312B1 (en) * 2001-10-10 2015-03-04 ratiopharm GmbH Remodelling and glycoconjugation of follicle-stimulating hormone (FSH)
SI2939696T1 (en) * 2001-10-18 2016-06-30 Nektar Therapeutics Polymer conjugates of opioid antagonists
AU2003241279A1 (en) * 2002-03-26 2003-10-13 Biosynexus Incorporated Antimicrobial polymer conjugates
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7459169B2 (en) * 2002-10-21 2008-12-02 Allvivo, Inc. Surface coating comprising bioactive compound
US7498415B2 (en) 2003-09-24 2009-03-03 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
US7790835B2 (en) 2003-12-03 2010-09-07 Nektar Therapeutics Method of preparing maleimide functionalized polymers
EP1893240A2 (en) * 2005-06-13 2008-03-05 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
US7301003B2 (en) * 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US20160151511A1 (en) * 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
US20170342211A1 (en) * 2016-05-31 2017-11-30 Robert Bosch Gmbh Azlactone functionalized substrates for conjugation of biomolecules
WO2018017190A2 (en) * 2016-06-01 2018-01-25 Baxalta Incorporated Formulations of polyalkylene oxide-asparaginase and methods of making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (en) * 1967-05-23 1971-08-02 Pharmacia Ab
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
US3674767A (en) * 1967-07-14 1972-07-04 Nat Res Dev Novel polymeric materials containing triazinyl groups

Also Published As

Publication number Publication date
DE2433883C2 (en) 1986-03-27
JPS5042087A (en) 1975-04-16
JPS5623587B2 (en) 1981-06-01
NL7409770A (en) 1975-01-22
CH616942A5 (en) 1980-04-30
SE441753B (en) 1985-11-04
CA1033673A (en) 1978-06-27
FR2313939B1 (en) 1979-05-18
FR2313939A1 (en) 1977-01-07
DE2433883A1 (en) 1976-02-05
IL45291A0 (en) 1974-10-22
GB1469472A (en) 1977-04-06

Similar Documents

Publication Publication Date Title
FR2313939B1 (en)
JPS546096A (en) Preparation of silyl-terminated polymer
ES462425A1 (en) Method of preparing novel bitumen compositions
ES426303A1 (en) Procedure for the obtaining of oxazolidine derivatives. (Machine-translation by Google Translate, not legally binding)
SE7412347L (en)
ES441678A1 (en) Polymerizates of olefinic nitriles
BE848604A (en) TETRAKIS-ALKYL-PIPERIDONE-4 SUBSTITUTED OXIMES FOR USE AS ORGANIC STABILIZERS,
SU480711A1 (en) The method of obtaining derivatives of 3-hydroxymethylthiazoline-2,4
GB1328706A (en) 2,6-dialkyl-3-hydroxy-6-beta-carboxyethyl-caclohex-2-en-1-ones
ES427869A1 (en) 5-phenyl-sulphinyl-2-benzimidazolyl-carbamic acid esters and process for their manufacture
ES390952A1 (en) Procedure for the preparation of 2-piperidilcarbinols. (Machine-translation by Google Translate, not legally binding)
ES412047A1 (en) Preparation of dihydrocoumarin and of alkyl derivatives thereof
DE3267690D1 (en) Process for the preparation of 3-alkyl-6-methyl-beta-resorcylic-acid esters
ES457416A1 (en) A procedure for the preparation of poly (tetrametileneter) glicol. (Machine-translation by Google Translate, not legally binding)
ES394637A1 (en) Vinyl esters polymers containing hindered phenolic groups
ES442022A1 (en) Phenylpropanolamines
GB1480045A (en) Hindered phenol derivatives of 9-thiabicyclononanes and stabilised compositions
SU593451A1 (en) METHOD FOR STABILIZATION
JPS5416466A (en) Novel 3-hydroxypyrrolldine-3-carboxylic derivative
JPS5247899A (en) Process for preparing polymers of norbornene derivatives
ES427622A1 (en) Procedure for the preparation of 2-amino-bencil-amines. (Machine-translation by Google Translate, not legally binding)
ES403328A1 (en) Novel bicycloalkane derivatives
ES384868A1 (en) A procedure for the preparation of pharmacodyamically active derivatives of hydroxyalcohylpiperazine. (Machine-translation by Google Translate, not legally binding)
ES420004A1 (en) Nitrosourea derivatives
ES432744A1 (en) Dibenzyl-glycolic acid derivatives

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 7409366-7

Effective date: 19940810

Format of ref document f/p: F